







Lab No. : SRE/27-01-2024/SR8673854

: PRIYANKA KUMARI

Age : 35 Y 6 M 25 D

Gender : F

Patient Name

Lab Add. : Newtown,Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 27/Jan/2024 10:02AM

Report Date : 27/Jan/2024 01:36PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit
CREATININE, BLOOD , GEL SERUM (Method:Jaffe, alkaline picrate, kinetic)	0.58	0.5-1.1	mg/dL
CHLORIDE,BLOOD (Method:ISE INDIRECT)	104	99-109	mEq/L
PHOSPHORUS-INORGANIC,BLOOD (Method:Phosphomolybdate/UV)	3.5	2.4-5.1 mg/dL	mg/dL
CALCIUM,BLOOD (Method:Arsenazo III)	9.80	8.7-10.4	mg/dL
POTASSIUM,BLOOD (Method:ISE INDIRECT)	4.30	3.5-5.5	mEq/L
GLUCOSE,PP (Method:Gluc Oxidase Trinder)	<u>191</u>	Impaired Glucose Tolerance-140 to 199.~Diabetes>= 200.	mg/dL

The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference

ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

UREA,BLOOD	19.3	19-49	mg/dL
(Method:Urease with GLDH)			
GLUCOSE,FASTING (Method:Gluc Oxidase Trinder)	<u>118</u>	Impaired Fasting-100-125 .~Diabetes- >= 126.~Fasting defined as no caloric intake f least 8 hours.	

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference:

ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

SODIUM,BLOOD	140	132 - 146	mEq/L	
(Method:ISE INDIRECT)				

*** End Of Report ***



Patient Name







Lab No. : SRE/27-01-2024/SR8673854 Lab Add

: PRIYANKA KUMARI

Age : 35 Y 6 M 25 D

Gender : F

Lab Add. : Newtown, Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

 Collection Date
 : 27/Jan/2024 10:02AM

 Report Date
 : 27/Jan/2024 01:36PM



DEPARTMENT OF BIOCHEMISTRY

Test Name Result Bio Ref. Interval Unit

Dr NEEPA CHOWDHURY MBBS MD (Biochemistry) Consultant Biochemist









Lab No. : SRE/27-01-2024/SR8673854 Lab Add. : Newtown.Kolkata-700156

Patient Name : PRIYANKA KUMARI Ref Dr. : Dr.MEDICAL OFFICER : 35 Y 6 M 25 D **Collection Date** : 27/Jan/2024 10:02AM

Gender :F Report Date : 27/Jan/2024 01:54PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit	
TOTAL PROTEIN [BLOOD] ALB:GLO RATION	0,.			
TOTAL PROTEIN (Method:BIURET METHOD)	7.90	5.7-8.2 g/dL	g/dL	
ALBUMIN (Method:BCG Dye Binding)	4.7	3.2-4.8 g/dL	g/dL	
GLOBULIN (Method:Calculated)	3.20	1.8-3.2	g/dl	
AG Ratio (Method:Calculated)	1.47	1.0-2.5		
THYROID PANEL (T3, T4, TSH), GEL SERUM				
T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA)	1.21	0.60-1.81 ng/ml	ng/ml	
T4-TOTAL (THYROXINE) (Method:CLIA)	<u>13.8</u>	3.2-12.6	μg/dL	
ESTIMATED TWICE				
TOUL/TUN/DOID OTIMALII ATIMO LIODAGONES	0.450	0.55.4.70	ull l/and	
TSH (THYROID STIMULATING HORMONE) (Method:CLIA)	2.456	0.55-4.78	μIU/mL	

Suggested follow up with ft4 report and to correlate clinically.

Serum TSH levels exhibit a diurnal variation with the peak occurring during the night and the nadir, which approximates to 50% of the peak value, occurring between 1000 and 1600 hours.[1,2]

References:

Age

1. Bugalho MJ, Domingues RS, Pinto AC, Garrao A, Catarino AL, Ferreira T, Limbert E and Sobrinho L. Detection of thyroglobulin mRNA transcripts in peripheral blood of

individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. Eur J Endocrinol 2001;145:409-13.

2. Bellantone R, Lombardi CP, Bossola M, Ferrante A, Princi P, Boscherini M et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrence varies according to the histologic type: results of a prospective study. Cancer 2001;92:2273-9.

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:

FIRST TRIMESTER: $0.10 - 3.00 \mu \text{ IU/mL}$ SECOND TRIMESTER: 0.20 -3.50 µ IU/mL THIRD TRIMESTER : $0.30 - 3.50 \,\mu$ IU/mL

References:

1. Erik K. Alexander, Elizabeth N. Pearce, Gregory A. Brent, Rosalind S. Brown, Herbert Chen, Chrysoula Dosiou, William A. Grobman, Peter Laurberg, John H. Lazarus, Susan J. Mandel, Robin P. Peeters, and Scott Sullivan. Thyroid. Mar 2017.315-389. http://doi.org/10.1089/thy.2016.0457 2. Kalra S, Agarwal S, Aggarwal R, Ranabir S. Trimester-specific thyroid-stimulating hormone: An indian perspective. Indian J Endocr Metab 2018;22:1-4.

URIC ACID,BLOOD	6.60	2.6-6.0	mg/dL
(Method:Uricase/Peroxidase)			

Correlate clinically.

Page 3 of 13 Lab No. SRE/27-01-2024/SR8673854









Page 4 of 13

 Patient Name
 : PRIYANKA KUMARI
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 35 Y 6 M 25 D

 Collection Date
 : 27/Jan/2024 10:02AM

Gender : F Report Date : 27/Jan/2024 01:54PM



DEPARTMENT OF BIOCHEMISTRY

Test Name Result Bio Ref. Interval Unit	
---	--

Suggested follow up.

GLYCATED HAEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C) 4.5 ***FOR BIOLOGICAL REFERENCE %

INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL

INFORMATION ***

HbA1c (IFCC) 26.0 mmol/mol

(Method:HPLC)

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Analyzer used :- Bio-Rad-VARIANT TURBO 2.0

Method: HPLC Cation Exchange

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- \emptyset For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B_{12} / folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

References:

- 1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
- 2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

PDF Attached

LIPID PROFILE, GEL SERUM			
CHOLESTEROL-TOTAL (Method:Enzymatic)	188	Desirable: < 200 mg/dL Borderline high: 200-239 mg/dL High: > or =240 mg/dL	mg/dL
TRIGLYCERIDES (Method:GPO-Trinder)	<u>190</u>	Normal:: < 150, BorderlineHigh::150-199, High:: 200-499, VeryHigh::>500	mg/dL
HDL CHOLESTEROL (Method:Elimination/catalase)	<u>35</u>	< 40 - Low 40-59- Optimum 60 - High	mg/dl
LDL CHOLESTEROL DIRECT (Method:Elimination / Catalase)	<u>149</u>	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100- 129 mg/dL, Borderline high: 130-159 mg/dL,	mg/dL









 Patient Name
 : PRIYANKA KUMARI
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 35 Y 6 M 25 D
 Collection Date
 : 27/Jan/2024 10:02AM

Gender : F Report Date : 27/Jan/2024 01:54PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit	
		High : 160-189 mg/dL, Very high : >=190 mg/dL		
VLDL (Method:Calculated)	4	< 40 mg/dl	mg/dl	
CHOL HDL Ratio (Method:Calculated)	5.4	LOW RISK 3.3-4.4 AVERAG 4.47-7.1 MODERATE RISK HIGH RISK >11.0		

Reference: National Cholesterol Education Program. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. May 16 2001;285(19):2486-97.

*** End Of Report ***

Dr. Sudeshna Baral M.B.B.S MD. (Biochemistry)

(Consultant Biochemist)

Page 5 of 13









 Patient Name
 : PRIYANKA KUMARI
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 35 Y 6 M 25 D
 Collection Date
 : 27/Jan/2024 10:05AM

Gender : F Report Date : 27/Jan/2024 02:19PM



DEPARTMENT OF HAEMATOLOGY

Test Name	Result	Bio Ref. Interval	Unit			
CBC WITH PLATELET (THROMBOCYTE) COUNT, EDTA WHOLE BLOOD						
HEMOGLOBIN	<u>10.6</u>	12 - 15	g/dL			
(Method:PHOTOMETRIC) WBC (Method:DC detection method)	7.0	4 - 10	*10^3/µL			
RBC (Method:DC detection method)	<u>3.27</u>	3.8 - 4.8	*10^6/µL			
PLATELET (THROMBOCYTE) COUNT (Method:DC detection method/Microscopy) DIFFERENTIAL COUNT	173	150 - 450*10^3	*10^3/µL			
NEUTROPHILS (Method:Flowcytometry/Microscopy)	57	40 - 80 %	%			
LYMPHOCYTES (Method:Flowcytometry/Microscopy)	35	20 - 40 %	%			
MONOCYTES (Method:Flowcytometry/Microscopy)	06	2 - 10 %	%			
EOSINOPHILS (Method:Flowcytometry/Microscopy)	02	1 - 6 %	%			
BASOPHILS (Method:Flowcytometry/Microscopy) CBC SUBGROUP	00	0-0.9%	%			
HEMATOCRIT / PCV (Method:Calculated)	<u>31.4</u>	36 - 46 %	%			
MCV (Method:Calculated)	96.1	83 - 101 fl	fl			
MCH (Method:Calculated)	<u>32.4</u>	27 - 32 pg	pg			
MCHC (Method:Calculated)	33.7	31.5-34.5 gm/dl	gm/dl			
RDW - RED CELL DISTRIBUTION WIDTH (Method:Calculated)	<u>16.5</u>	11.6-14%	%			
PDW-PLATELET DISTRIBUTION WIDTH (Method:Calculated)	28.4	8.3 - 25 fL	fL			
MPV-MEAN PLATELET VOLUME (Method:Calculated)	12.6	7.5 - 11.5 fl				

*** End Of Report ***

Bidisha Challenberry

Dr. Bidisha Challenborry

Consultant Pathologist

Consultant Pathologist MD, DNB (Pathology) Dip RC Path(UK)









Patient Name : PRIYANKA KUMARI Ref Dr. : Dr.MEDICAL OFFICER

 Age
 : 35 Y 6 M 25 D

 Collection Date
 : 27/Jan/2024 10:05AM

Gender : F Report Date : 27/Jan/2024 04:56PM



DEPARTMENT OF HAEMATOLOGY

Test Name Result Bio Ref. Interval Unit

ESR (ERYTHROCYTE SEDIMENTATION RATE), EDTA WHOLE BLOOD

1stHour 32 0.00 - 20.00 mm/hr mm/hr

(Method:Westergren)

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

ABO O

(Method:Gel Card)

RH POSITIVE

(Method:Gel Card)

TECHNOLOGY USED: GEL METHOD

ADVANTAGES:

- · Gel card allows simultaneous forward and reverse grouping.
- · Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

*** End Of Report ***

Kaushik Dey

MD (PATHOLOGY)
CONSULTANT PATHOLOGIST

Lab No. : SRE/27-01-2024/SR8673854 Page 7 of 13



Patient Name : PRIYANKA KUMARI Ref Dr. : Dr.MEDICAL OFFICER

Age : 35 Y 6 M 25 D Collection Date :

Gender : F Report Date : 27/Jan/2024 02:13PM



DEPARTMENT OF RADIOLOGY X-RAY REPORT OF CHEST (PA)

FINDINGS:

No active lung parenchymal lesion is seen.

Both the hila are normal in size, density and position.

Mediastinum is central. Trachea is in midline.

Domes of diaphragm are smoothly outlined. Position is within normal limits.

Lateral costo-phrenic angles are clear.

The cardio-thoracic ratio is normal.

Bony thorax reveals no definite abnormality.

IMPRESSION:

Normal study.

*** End Of Report ***

Dr.Tanvi Priyam MBBS, MD Radio-Diagnosis WB 81485

Lab No. : SRE/27-01-2024/SR8673854 Page 8 of 13









Lab No. : SRE/27-01-2024/SR8673854 Lab Add. : Newtown.Kolkata-700156

Patient Name : PRIYANKA KUMARI Ref Dr. : Dr.MEDICAL OFFICER

: 35 Y 6 M 25 D **Collection Date** : 28/Jan/2024 11:24AM Age

Gender : F Report Date : 28/Jan/2024 05:06PM



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name	Result	Bio Ref. Interval	Unit	
URINE ROUTINE ALL, ALL, URINE				
DIN(010 41 E)(4141114 E1011				

URINE ROUTINE ALL, ALL, URINE			
PHYSICAL EXAMINATION			
COLOUR	PALE YELLOW		
APPEARANCE	SLIGHTLY HAZY		
CHEMICAL EXAMINATION			
pH	5.0	4.6 - 8.0	
(Method:Dipstick (triple indicator method))			
SPECIFIC GRAVITY	1.015	1.005 - 1.030	
(Method:Dipstick (ion concentration method))			
PROTEIN	NOT DETECTED	NOT DETECTED	
(Method:Dipstick (protein error of pH			
indicators)/Manual) GLUCOSE	NOT DETECTED	NOT DETECTED	
(Method:Dipstick(glucose-oxidase-peroxidase	NOT DETECTED	NOT DETECTED	
method)/Manual)			
KETONES (ACETOACETIC ACID,	NOT DETECTED	NOT DETECTED	
ACETONE)			
(Method:Dipstick (Legals test)/Manual)			
BLOOD	NOT DETECTED	NOT DETECTED	
(Method:Dipstick (pseudoperoxidase reaction))			
BILIRUBIN	NEGATIVE	NEGATIVE	
(Method:Dipstick (azo-diazo reaction)/Manual)			
UROBILINOGEN	NEGATIVE	NEGATIVE	
(Method:Dipstick (diazonium ion reaction)/Manual) NITRITE	NEGATIVE	NEGATIVE	
(Method:Dipstick (Griess test))	NEGATIVE	NEGATIVE	
LEUCOCYTE ESTERASE	NEGATIVE	NEGATIVE	
(Method:Dipstick (ester hydrolysis reaction))	NEGATIVE	NEGATIVE	
MICROSCOPIC EXAMINATION			
LEUKOCYTES (PUS CELLS)	0-1	0-5	/hpf
(Method:Microscopy)	U- I	0-3	/TIPI
EPITHELIAL CELLS	8-10	0-5	/hpf
(Method:Microscopy)	- · -		· 1
RED BLOOD CELLS	NOT DETECTED	0-2	/hpf
(Method:Microscopy)			·
CAST	NOT DETECTED	NOT DETECTED	
(Method:Microscopy)			
CRYSTALS	CALCIUM OXALATE	NOT DETECTED	
(Method:Microscopy)	PRESENT		
BACTERIA	SCANTY	NOT DETECTED	
(Method:Microscopy)	NOT DETECTED	NOT DETECTED	
YEAST (Mathed Microscopy)	NOT DETECTED	NOT DETECTED	
(Method:Microscopy)			

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.

Page 9 of 13 SRE/27-01-2024/SR8673854 Lab No.









Patient Name : PRIYANKA KUMARI Ref Dr. : Dr.MEDICAL OFFICER

 Age
 : 35 Y 6 M 25 D
 Collection Date
 : 28/Jan/2024 11:24AM

Gender : F Report Date : 28/Jan/2024 05:06PM



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

*** End Of Report ***

Dr Mansi Gulati Consultant Pathologist MBBS, MD, DNB (Pathology)

Lab No. : SRE/27-01-2024/SR8673854 Page 10 of 13



Lab No. : SRE/27-01-2024/SR8673854 Lab Add.

Patient Name : PRIYANKA KUMARI Ref Dr. : Dr.MEDICAL OFFICER

Age : 35 Y 6 M 25 D Collection Date :

Gender : F Report Date : 27/Jan/2024 03:57PM



DEPARTMENT OF CARDIOLOGY

E.C.G. REPORT

Heart rate - 68 / min. (average)

Rhythm - Sinus

Axis - Normal

P- Wave - Normal

PR Interval - 0.12 Sec.

QRS Complexes - Normal

ST Segment - Isoelectric

T Wave - Normal

QT Interval - 0.40 Sec.

Voltage - Normal

IMPRESSION: Normal Tracing. Please correlate clinically.

*** End Of Report ***

Dr SANIAY SUD MBBS (Cal), FCCP, MRI PHH(UK) ECHO CARDIOLOGIST

Page 11 of 13



Patient Name : PRIYANKA KUMARI Ref Dr. : Dr.MEDICAL OFFICER

Age : 35 Y 6 M 25 D Collection Date :

Gender : F Report Date : 27/Jan/2024 12:09PM



DEPARTMENT OF ULTRASONOGRAPHY

REPORT ON EXAMINATION OF WHOLE ABDOMEN

LIVER

Liver is enlarged in size (16.72 cm), having grade I fatty changes. No focal parenchymal lesion is evident. Intrahepatic biliary radicles are not dilated. Branches of portal vein are normal.

PORTA

The appearance of porta is normal. Common bile duct is normal (0.40 cm) with no intraluminal pathology (calculi /mass) could be detected at its visualized part. Portal vein is normal (1.00 cm) at porta.

GALLBLADDER

Gallbladder is distended. Wall thickness appears normal. No intraluminal pathology (calculi/mass) could be detected. Sonographic Murphys sign is negative.

PANCREAS

Echogenecity appears within limits, without any focal lesion. Shape, size & position appears normal. No Calcular disease noted. Pancreatic duct is not dilated. No peri-pancreatic collection of fluid noted.

SPLEEN

Spleen is enlarged in size (**15.09 cm**). Homogenous and smooth echotexture without any focal lesion. Splenic vein at hilum appears normal. No definite collaterals could be detected.

KIDNEYS

Both kidneys are normal in shape, size (Rt. Kidney 11.33 cm. & Lt. kidney 11.02 cm.) axes & position. Cortical echogenecity appears normal maintaining cortico-medullary differentiation. Margin is regular and cortical thickness is uniform. No calcular disease noted. No hydronephrotic changes detected.

Visualized parts of upper ureters are not dilated.

URINARY BLADDER

Urinary bladder is distended, wall thickness appeared normal. No intraluminal pathology (calculi/mass) could be detected.

UTERUS

Uterus is ante-verted, normal in size (8.75 cm x 4.61 cm x 5.40 cm). Endometrium (0.80 cm) is in midline. Myometrium appears smooth & homogenous without any detectable/sizable focal lesion.

Cervix looks normal. Pouch of Douglas is free.

ADNEXA

Adnexa appear clear with no obvious mass lesion could be detected.

OVARIES

Ovaries are normal in size, shape, position, margin and echotexture.

Lab No. : SRE/27-01-2024/SR8673854

Page 12 of 13



 Patient Name
 : PRIYANKA KUMARI
 Ref Dr.
 : Dr.MEDICAL OFFICER

Age : 35 Y 6 M 25 D Collection Date

Gender : F Report Date : 27/Jan/2024 12:09PM

Right ovary measures: 2.59 cm x 2.66 cm.

Left ovary measures : 2.94 cm x 2.82 cm.

RETROPERITONEUM & PERITONEUM

No ascites noted. No definite evidence of any mass lesion detected. No detectable evidence of enlarged lymph nodes noted. Visualized part of aorta & IVC are within normal limit.

IMPRESSION:

- 1) Hepatomegaly with grade I fatty changes.
- 2) Splenomegaly.

KINDLY NOTE

Ultrasound is not the modality of choice to rule out subtle bowel lesion.

Please Intimate us for any typing mistakes and send the report for correction within 7 days.

The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive.

Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

The report and films are not valid for medico-legal purpose.

Patient Identity not verified

DR. S. K. MONDAL MBBS, CBET (Sonologist)

Page 13 of 13

SURAKSHA DIAGNOSTIC,RAJARHAT,KOLKATA BIO-RAD VARIANT-II TURBO CDM5.4. SN-16122

PATIENT REPORT V2TURBO_A1c_2.0

Patient Data Analysis Data

Sample ID: D02135515271 Analysis Performed: 27/JAN/2024 14:43:15

 Patient ID:
 SR8673854
 Injection Number:
 10403U

 Name:
 Run Number:
 202

 Physician:
 Rack ID:
 0003

 Sex:
 Tube Number:
 6

DOB: Report Generated: 27/JAN/2024 15:03:31

Operator ID: TRISHA

Comments:

	NGSP		Retention	Peak
Peak Name	%	Area %	Time (min)	Area
A1a		0.9	0.168	19479
A1b		0.6	0.232	11912
F		1.1	0.281	22416
LA1c		1.8	0.402	36824
A1c	4.5		0.512	74687
P3		3.0	0.784	62439
P4		0.9	0.868	17814
Ao		88.1	0.988	1826125

Total Area: 2,071,696

HbA1c (NGSP) = 4.5 % HbA1c (IFCC) = 26 mmol/mol

